Skip to main content

Plegridy FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 3, 2021.

FDA Approved: Yes (First approved August 15, 2014)
Brand name: Plegridy
Generic name: peginterferon beta-1a
Dosage form: Injection
Company: Biogen Inc.
Treatment for: Multiple Sclerosis

Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Development timeline for Plegridy

DateArticle
Feb  1, 2021Approval Biogen Announces FDA Approval of Plegridy (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Aug 18, 2014Approval FDA Approves Plegridy (peginterferon beta-1a) for the Treatment of Multiple Sclerosis
Jul 19, 2013US and EU Regulatory Authorities Accept Plegridy (peginterferon beta-1a) Marketing Applications for Review
May 21, 2013Biogen Idec Submits Application to FDA for Approval of Plegridy (Peginterferon Beta-1a) in Multiple Sclerosis

See also

Plegridy (peginterferon beta-1a) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer